{"product_id":"sobetiromegc-1","title":"Sobetirome(GC-1) 10.000mcg sublingual\/oral vial","description":"\u003cp data-end=\"724\" data-start=\"187\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                             \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"164\" data-end=\"742\"\u003e\u003cstrong\u003eSobetirome\u003c\/strong\u003e is an \u003cstrong data-start=\"214\" data-end=\"265\"\u003eoral, small-molecule TRβ-selective thyromimetic\u003c\/strong\u003e designed to deliver the \u003cstrong data-start=\"290\" data-end=\"345\"\u003elipid-lowering and hepatic\/metabolic benefits of T3\u003c\/strong\u003e while minimizing \u003cstrong data-start=\"363\" data-end=\"404\"\u003eTRα-mediated cardiac and bone effects\u003c\/strong\u003e. By activating \u003cstrong data-start=\"420\" data-end=\"427\"\u003eTRβ\u003c\/strong\u003e(highly expressed in \u003cstrong data-start=\"449\" data-end=\"458\"\u003eliver\u003c\/strong\u003e and \u003cstrong data-start=\"463\" data-end=\"494\"\u003eCNS oligodendrocyte lineage\u003c\/strong\u003e), sobetirome increases \u003cstrong data-start=\"518\" data-end=\"553\"\u003ehepatic LDL-receptor expression\u003c\/strong\u003e, enhances \u003cstrong data-start=\"564\" data-end=\"597\"\u003ereverse cholesterol transport\u003c\/strong\u003e, \u003cstrong data-start=\"599\" data-end=\"634\"\u003estimulates fatty-acid oxidation\u003c\/strong\u003e, and \u003cstrong data-start=\"640\" data-end=\"691\"\u003ereprograms bile-acid and lipoprotein metabolism\u003c\/strong\u003e. It is \u003cstrong data-start=\"699\" data-end=\"718\"\u003einvestigational\u003c\/strong\u003e (not FDA\/EMA-approved).\u003c\/p\u003e\n\u003chr data-start=\"744\" data-end=\"747\"\u003e\n\u003ch3 data-start=\"749\" data-end=\"810\"\u003eAdditional Benefits of Sobetirome Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"812\" data-end=\"3128\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"812\" data-end=\"840\"\u003e\n\u003ctr data-start=\"812\" data-end=\"840\"\u003e\n\u003cth data-start=\"812\" data-end=\"822\" data-col-size=\"sm\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"822\" data-end=\"840\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"851\" data-end=\"3128\"\u003e\n\u003ctr data-start=\"851\" data-end=\"1144\"\u003e\n\u003ctd data-start=\"851\" data-end=\"887\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"853\" data-end=\"886\"\u003e1 LDL-C and non-HDL reduction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"887\" data-end=\"1144\" data-col-size=\"xl\"\u003eDose-dependent \u003cstrong data-start=\"904\" data-end=\"913\"\u003eLDL-C\u003c\/strong\u003e and \u003cstrong data-start=\"918\" data-end=\"934\"\u003eapoB\/non-HDL\u003c\/strong\u003e lowering via TRβ-driven \u003cstrong data-start=\"959\" data-end=\"981\"\u003eLDLR up-regulation\u003c\/strong\u003e and increased cholesterol disposal; add-on to statins shows \u003cstrong data-start=\"1042\" data-end=\"1059\"\u003ecomplementary\u003c\/strong\u003e effects. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Clinical Endocrinology \u0026amp; Metabolism; Circulation\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1145\" data-end=\"1387\"\u003e\n\u003ctd data-start=\"1145\" data-end=\"1190\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1147\" data-end=\"1189\"\u003e2 Triglycerides \u0026amp; remnant lipoproteins\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1190\" data-end=\"1387\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"1192\" data-end=\"1207\"\u003eHepatic FAO\u003c\/strong\u003e and \u003cstrong data-start=\"1212\" data-end=\"1234\"\u003eVLDL output tuning\u003c\/strong\u003e reduce \u003cstrong data-start=\"1242\" data-end=\"1256\"\u003efasting TG\u003c\/strong\u003e and remnant cholesterol; small HDL-C shifts vary by dose and background therapy. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Atherosclerosis; J Lipid Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1388\" data-end=\"1640\"\u003e\n\u003ctd data-start=\"1388\" data-end=\"1416\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1390\" data-end=\"1415\"\u003e3 NAFLD\/MASH activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1416\" data-end=\"1640\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"1418\" data-end=\"1430\"\u003eMRI-PDFF\u003c\/strong\u003e and enzyme improvements with \u003cstrong data-start=\"1460\" data-end=\"1475\"\u003esteatosis ↓\u003c\/strong\u003e; transcriptional programs favor \u003cstrong data-start=\"1508\" data-end=\"1523\"\u003eβ-oxidation\u003c\/strong\u003eand \u003cstrong data-start=\"1528\" data-end=\"1541\"\u003elipophagy\u003c\/strong\u003e, with anti-inflammatory signals downstream of TRβ. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Hepatology; Liver International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1641\" data-end=\"1865\"\u003e\n\u003ctd data-start=\"1641\" data-end=\"1661\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1643\" data-end=\"1660\"\u003e4 Lp(a) trend\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1661\" data-end=\"1865\" data-col-size=\"xl\"\u003eEarly clinical signals suggest \u003cstrong data-start=\"1694\" data-end=\"1719\"\u003emodest Lp(a) lowering\u003c\/strong\u003e (magnitude study-dependent); mechanism likely via \u003cstrong data-start=\"1770\" data-end=\"1808\"\u003ehepatic transcriptional remodeling\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;European Heart Journal; JAMA Cardiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1866\" data-end=\"2114\"\u003e\n\u003ctd data-start=\"1866\" data-end=\"1910\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1868\" data-end=\"1909\"\u003e5 Energy expenditure \u0026amp; weight signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1910\" data-end=\"2114\" data-col-size=\"xl\"\u003eMild \u003cstrong data-start=\"1917\" data-end=\"1949\"\u003e↑ resting energy expenditure\u003c\/strong\u003e and \u003cstrong data-start=\"1954\" data-end=\"1973\"\u003ewaist reduction\u003c\/strong\u003e in dyslipidemic\/NAFLD phenotypes without frank hyperthyroid symptoms at TRβ-selective exposures. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Cell Metabolism; Metabolism\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2115\" data-end=\"2322\"\u003e\n\u003ctd data-start=\"2115\" data-end=\"2149\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2117\" data-end=\"2148\"\u003e6 Combination lipid therapy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2149\" data-end=\"2322\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"2151\" data-end=\"2179\"\u003eAdditive LDL-C reduction\u003c\/strong\u003e with \u003cstrong data-start=\"2185\" data-end=\"2196\"\u003estatins\u003c\/strong\u003e or \u003cstrong data-start=\"2200\" data-end=\"2213\"\u003eezetimibe\u003c\/strong\u003e; potential synergy with \u003cstrong data-start=\"2238\" data-end=\"2258\"\u003ePCSK9 inhibitors\u003c\/strong\u003e for aggressive apoB lowering. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Circulation; JCEM\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2323\" data-end=\"2592\"\u003e\n\u003ctd data-start=\"2323\" data-end=\"2362\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2325\" data-end=\"2361\"\u003e7 Atheroprotection (preclinical)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2362\" data-end=\"2592\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"2364\" data-end=\"2388\"\u003ePlaque cholesterol ↓\u003c\/strong\u003e, improved \u003cstrong data-start=\"2399\" data-end=\"2424\"\u003elesional inflammation\u003c\/strong\u003e and \u003cstrong data-start=\"2429\" data-end=\"2450\"\u003emacrophage efflux\u003c\/strong\u003e (ABCA1\/ABCG1) in models; outcomes trials pending. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Arteriosclerosis, Thrombosis, and Vascular Biology; Cardiovascular Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2593\" data-end=\"2851\"\u003e\n\u003ctd data-start=\"2593\" data-end=\"2627\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2595\" data-end=\"2626\"\u003e8 CNS myelin\/repair biology\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2627\" data-end=\"2851\" data-col-size=\"xl\"\u003eTRβ activation promotes \u003cstrong data-start=\"2653\" data-end=\"2688\"\u003eoligodendrocyte differentiation\u003c\/strong\u003e and \u003cstrong data-start=\"2693\" data-end=\"2710\"\u003eremyelination\u003c\/strong\u003e; \u003cstrong data-start=\"2712\" data-end=\"2749\"\u003ebrain-penetrant prodrug (Sob-AM2)\u003c\/strong\u003e enhances CNS exposure and \u003cstrong data-start=\"2776\" data-end=\"2793\"\u003elowers VLCFAs\u003c\/strong\u003e in ALD models. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Brain; Annals of Neurology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2852\" data-end=\"3128\"\u003e\n\u003ctd data-start=\"2852\" data-end=\"2898\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2854\" data-end=\"2897\"\u003e9 Very-long-chain fatty acids (ALD\/AMN)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2898\" data-end=\"3128\" data-col-size=\"xl\"\u003eSobetirome (± prodrug) \u003cstrong data-start=\"2923\" data-end=\"2947\"\u003ereduces C26:0 VLCFAs\u003c\/strong\u003e in \u003cstrong data-start=\"2951\" data-end=\"2970\"\u003eABCD1-deficient\u003c\/strong\u003e models; early human translational work is ongoing for \u003cstrong data-start=\"3025\" data-end=\"3058\"\u003eX-linked adrenoleukodystrophy\u003c\/strong\u003e phenotypes. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Science Translational Medicine; Neurology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3130\" data-end=\"3133\"\u003e\n\u003ch2 data-start=\"3135\" data-end=\"3170\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"3172\" data-end=\"3207\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cul data-start=\"3208\" data-end=\"3553\"\u003e\n\u003cli data-start=\"3208\" data-end=\"3265\"\u003e\n\u003cp data-start=\"3210\" data-end=\"3265\"\u003e\u003cstrong data-start=\"3210\" data-end=\"3221\"\u003eTarget:\u003c\/strong\u003e \u003cstrong data-start=\"3222\" data-end=\"3247\"\u003eTRβ-selective agonism\u003c\/strong\u003e (liver-biased).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3266\" data-end=\"3441\"\u003e\n\u003cp data-start=\"3268\" data-end=\"3441\"\u003e\u003cstrong data-start=\"3268\" data-end=\"3288\"\u003eHepatic actions:\u003c\/strong\u003e ↑ \u003cstrong data-start=\"3291\" data-end=\"3299\"\u003eLDLR\u003c\/strong\u003e, \u003cstrong data-start=\"3301\" data-end=\"3311\"\u003eCYP7A1\u003c\/strong\u003e\/\u003cstrong data-start=\"3312\" data-end=\"3335\"\u003ebile-acid synthesis\u003c\/strong\u003e, \u003cstrong data-start=\"3337\" data-end=\"3358\"\u003eβ-oxidation genes\u003c\/strong\u003e; ↓ \u003cstrong data-start=\"3362\" data-end=\"3386\"\u003eSREBP-1c lipogenesis\u003c\/strong\u003e → \u003cstrong data-start=\"3389\" data-end=\"3410\"\u003eLDL-C\/TG lowering\u003c\/strong\u003e and \u003cstrong data-start=\"3415\" data-end=\"3438\"\u003esteatosis reduction\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3442\" data-end=\"3553\"\u003e\n\u003cp data-start=\"3444\" data-end=\"3553\"\u003e\u003cstrong data-start=\"3444\" data-end=\"3475\"\u003eCNS actions (experimental):\u003c\/strong\u003e \u003cstrong data-start=\"3476\" data-end=\"3508\"\u003eTRβ in OPCs\/oligodendrocytes\u003c\/strong\u003e → \u003cstrong data-start=\"3511\" data-end=\"3526\"\u003emyelin gene\u003c\/strong\u003e expression and maturation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3555\" data-end=\"3582\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3584\" data-end=\"3976\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3584\" data-end=\"3626\"\u003e\n\u003ctr data-start=\"3584\" data-end=\"3626\"\u003e\n\u003cth data-start=\"3584\" data-end=\"3594\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3594\" data-end=\"3615\" data-col-size=\"sm\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3615\" data-end=\"3626\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3641\" data-end=\"3976\"\u003e\n\u003ctr data-start=\"3641\" data-end=\"3736\"\u003e\n\u003ctd data-start=\"3641\" data-end=\"3679\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3643\" data-end=\"3678\"\u003eTRβ → LDLR, bile-acid synthesis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3679\" data-end=\"3720\" data-col-size=\"sm\"\u003ePlasma LDL-C ↓, cholesterol disposal ↑\u003c\/td\u003e\n\u003ctd data-start=\"3720\" data-end=\"3736\" data-col-size=\"sm\"\u003eLiver\/lipids\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3737\" data-end=\"3804\"\u003e\n\u003ctd data-start=\"3737\" data-end=\"3773\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3739\" data-end=\"3772\"\u003ePPAR-coordinated FAO programs\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3773\" data-end=\"3795\" data-col-size=\"sm\"\u003eTG ↓, hepatic fat ↓\u003c\/td\u003e\n\u003ctd data-start=\"3795\" data-end=\"3804\" data-col-size=\"sm\"\u003eLiver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3805\" data-end=\"3884\"\u003e\n\u003ctd data-start=\"3805\" data-end=\"3830\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3807\" data-end=\"3829\"\u003eABCA1\/ABCG1 efflux\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3830\" data-end=\"3864\" data-col-size=\"sm\"\u003eMacrophage cholesterol efflux ↑\u003c\/td\u003e\n\u003ctd data-start=\"3864\" data-end=\"3884\" data-col-size=\"sm\"\u003eAtheroprotection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3885\" data-end=\"3976\"\u003e\n\u003ctd data-start=\"3885\" data-end=\"3927\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3887\" data-end=\"3926\"\u003eOPC differentiation genes (MBP\/MOG)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3927\" data-end=\"3951\" data-col-size=\"sm\"\u003eRemyelination support\u003c\/td\u003e\n\u003ctd data-start=\"3951\" data-end=\"3976\" data-col-size=\"sm\"\u003eCNS (prodrug-enabled)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3978\" data-end=\"3981\"\u003e\n\u003ch2 data-start=\"3983\" data-end=\"4005\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"4007\" data-end=\"4436\"\u003e\n\u003cli data-start=\"4007\" data-end=\"4053\"\u003e\n\u003cp data-start=\"4009\" data-end=\"4053\"\u003e\u003cstrong data-start=\"4009\" data-end=\"4019\"\u003eRoute:\u003c\/strong\u003e \u003cstrong data-start=\"4020\" data-end=\"4028\"\u003eOral\u003c\/strong\u003e, once-daily in trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4054\" data-end=\"4125\"\u003e\n\u003cp data-start=\"4056\" data-end=\"4125\"\u003e\u003cstrong data-start=\"4056\" data-end=\"4071\"\u003eAbsorption:\u003c\/strong\u003e Rapid; food effect modest (not clinically central).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4126\" data-end=\"4211\"\u003e\n\u003cp data-start=\"4128\" data-end=\"4211\"\u003e\u003cstrong data-start=\"4128\" data-end=\"4142\"\u003eHalf-life:\u003c\/strong\u003e \u003cstrong data-start=\"4143\" data-end=\"4157\"\u003eMulti-hour\u003c\/strong\u003e (supports QD dosing); hepatic distribution favored.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4212\" data-end=\"4312\"\u003e\n\u003cp data-start=\"4214\" data-end=\"4312\"\u003e\u003cstrong data-start=\"4214\" data-end=\"4239\"\u003eMetabolism\/clearance:\u003c\/strong\u003e Oxidative\/phase-II metabolism; biliary\/renal excretion of metabolites.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4313\" data-end=\"4436\"\u003e\n\u003cp data-start=\"4315\" data-end=\"4436\"\u003e\u003cstrong data-start=\"4315\" data-end=\"4336\"\u003eProdrug strategy:\u003c\/strong\u003e \u003cstrong data-start=\"4337\" data-end=\"4348\"\u003eSob-AM2\u003c\/strong\u003e increases \u003cstrong data-start=\"4359\" data-end=\"4377\"\u003ebrain exposure\u003c\/strong\u003e for CNS targets while limiting systemic thyromimetic load.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4438\" data-end=\"4441\"\u003e\n\u003ch2 data-start=\"4443\" data-end=\"4483\"\u003e4. Pre-clinical and Clinical Evidence\u003c\/h2\u003e\n\u003ch3 data-start=\"4485\" data-end=\"4530\"\u003e4.1 Dyslipidemia \/ Mixed hyperlipidemia\u003c\/h3\u003e\n\u003cp data-start=\"4531\" data-end=\"4788\"\u003ePhase 1\/2 programs demonstrate \u003cstrong data-start=\"4562\" data-end=\"4609\"\u003eclinically relevant LDL-C and TG reductions\u003c\/strong\u003e with favorable \u003cstrong data-start=\"4625\" data-end=\"4641\"\u003eapoB\/non-HDL\u003c\/strong\u003e changes and \u003cstrong data-start=\"4654\" data-end=\"4673\"\u003eTSH suppression\u003c\/strong\u003e consistent with on-target thyroid signaling—without significant \u003cstrong data-start=\"4738\" data-end=\"4762\"\u003eTRα-like tachycardia\u003c\/strong\u003e at therapeutic exposures.\u003c\/p\u003e\n\u003ch3 data-start=\"4790\" data-end=\"4812\"\u003e4.2 NAFLD \/ MASH\u003c\/h3\u003e\n\u003cp data-start=\"4813\" data-end=\"5006\"\u003eImaging\/lab signals show \u003cstrong data-start=\"4838\" data-end=\"4863\"\u003ehepatic-fat reduction\u003c\/strong\u003e and \u003cstrong data-start=\"4868\" data-end=\"4892\"\u003eALT\/AST improvements\u003c\/strong\u003e, aligning with the hepatic TRβ mechanism. Histologic outcomes are being pursued in class programs (TRβ agonists).\u003c\/p\u003e\n\u003ch3 data-start=\"5008\" data-end=\"5044\"\u003e4.3 CNS (ALD\/MS translational)\u003c\/h3\u003e\n\u003cp data-start=\"5045\" data-end=\"5238\"\u003eSobetirome and \u003cstrong data-start=\"5060\" data-end=\"5087\"\u003ebrain-targeted prodrugs\u003c\/strong\u003e reduce \u003cstrong data-start=\"5095\" data-end=\"5105\"\u003eVLCFAs\u003c\/strong\u003e and \u003cstrong data-start=\"5110\" data-end=\"5135\"\u003eimprove remyelination\u003c\/strong\u003e indices in animals; early human translational efforts are underway (biomarkers, safety, and exposure).\u003c\/p\u003e\n\u003cblockquote data-start=\"5240\" data-end=\"5462\"\u003e\n\u003cp data-start=\"5242\" data-end=\"5462\"\u003e\u003cstrong data-start=\"5242\" data-end=\"5268\"\u003eEvidence quality note:\u003c\/strong\u003e Robust \u003cstrong data-start=\"5276\" data-end=\"5291\"\u003emechanistic\u003c\/strong\u003e and \u003cstrong data-start=\"5296\" data-end=\"5311\"\u003epreclinical\u003c\/strong\u003e data; \u003cstrong data-start=\"5318\" data-end=\"5339\"\u003eearly-phase human\u003c\/strong\u003e trials show lipid\/steatosis signals. Hard outcomes (CV events, MASH histology, neurologic disability) remain \u003cstrong data-start=\"5449\" data-end=\"5461\"\u003eunproven\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"5464\" data-end=\"5467\"\u003e\n\u003ch2 data-start=\"5469\" data-end=\"5502\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"5504\" data-end=\"6070\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"5504\" data-end=\"5534\"\u003e\n\u003ctr data-start=\"5504\" data-end=\"5534\"\u003e\n\u003cth data-start=\"5504\" data-end=\"5512\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"5512\" data-end=\"5524\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"5524\" data-end=\"5534\" data-col-size=\"sm\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"5549\" data-end=\"6070\"\u003e\n\u003ctr data-start=\"5549\" data-end=\"5638\"\u003e\n\u003ctd data-start=\"5549\" data-end=\"5580\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5551\" data-end=\"5579\"\u003eApoB-driven dyslipidemia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5580\" data-end=\"5613\" data-col-size=\"md\"\u003eHepatic TRβ LDLR up-regulation\u003c\/td\u003e\n\u003ctd data-start=\"5613\" data-end=\"5638\" data-col-size=\"sm\"\u003ePhase 2–style signals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5639\" data-end=\"5727\"\u003e\n\u003ctd data-start=\"5639\" data-end=\"5672\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5641\" data-end=\"5671\"\u003eStatin-intolerant \/ add-on\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5672\" data-end=\"5708\" data-col-size=\"md\"\u003eNon-myotoxic mechanism, stackable\u003c\/td\u003e\n\u003ctd data-start=\"5708\" data-end=\"5727\" data-col-size=\"sm\"\u003eInvestigational\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5728\" data-end=\"5781\"\u003e\n\u003ctd data-start=\"5728\" data-end=\"5745\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5730\" data-end=\"5744\"\u003eNAFLD\/MASH\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5745\" data-end=\"5770\" data-col-size=\"md\"\u003eSteatosis ↓, enzymes ↓\u003c\/td\u003e\n\u003ctd data-start=\"5770\" data-end=\"5781\" data-col-size=\"sm\"\u003eOngoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5782\" data-end=\"5890\"\u003e\n\u003ctd data-start=\"5782\" data-end=\"5828\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5784\" data-end=\"5827\"\u003eFamilial hypercholesterolemia (adjunct)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5828\" data-end=\"5875\" data-col-size=\"md\"\u003eAdditional LDL-C lowering with PCSK9\/statins\u003c\/td\u003e\n\u003ctd data-start=\"5875\" data-end=\"5890\" data-col-size=\"sm\"\u003eExploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5891\" data-end=\"5961\"\u003e\n\u003ctd data-start=\"5891\" data-end=\"5914\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5893\" data-end=\"5913\"\u003eX-linked ALD\/AMN\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5914\" data-end=\"5944\" data-col-size=\"md\"\u003eVLCFA lowering; CNS prodrug\u003c\/td\u003e\n\u003ctd data-start=\"5944\" data-end=\"5961\" data-col-size=\"sm\"\u003eTranslational\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5962\" data-end=\"6070\"\u003e\n\u003ctd data-start=\"5962\" data-end=\"5995\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5964\" data-end=\"5994\"\u003eMS remyelination (concept)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5995\" data-end=\"6035\" data-col-size=\"md\"\u003eTRβ-driven oligodendrocyte maturation\u003c\/td\u003e\n\u003ctd data-start=\"6035\" data-end=\"6070\" data-col-size=\"sm\"\u003ePreclinical\/early translational\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6072\" data-end=\"6075\"\u003e\n\u003ch2 data-start=\"6077\" data-end=\"6106\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"6108\" data-end=\"6998\"\u003e\n\u003cli data-start=\"6108\" data-end=\"6298\"\u003e\n\u003cp data-start=\"6110\" data-end=\"6298\"\u003e\u003cstrong data-start=\"6110\" data-end=\"6138\"\u003eClass\/on-target effects:\u003c\/strong\u003e \u003cstrong data-start=\"6139\" data-end=\"6158\"\u003eTSH suppression\u003c\/strong\u003e, \u003cstrong data-start=\"6160\" data-end=\"6181\"\u003eT3\/T4 axis shifts\u003c\/strong\u003e (generally mild); \u003cstrong data-start=\"6200\" data-end=\"6214\"\u003eheart-rate\u003c\/strong\u003e\/palpitations uncommon at TRβ-selective exposures but possible with over-exposure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6299\" data-end=\"6423\"\u003e\n\u003cp data-start=\"6301\" data-end=\"6423\"\u003e\u003cstrong data-start=\"6301\" data-end=\"6316\"\u003eCommon AEs:\u003c\/strong\u003e \u003cstrong data-start=\"6317\" data-end=\"6329\"\u003eHeadache\u003c\/strong\u003e, \u003cstrong data-start=\"6331\" data-end=\"6343\"\u003eGI upset\u003c\/strong\u003e, \u003cstrong data-start=\"6345\" data-end=\"6362\"\u003emild insomnia\u003c\/strong\u003e, \u003cstrong data-start=\"6364\" data-end=\"6380\"\u003ewarmth\/flush\u003c\/strong\u003e, \u003cstrong data-start=\"6382\" data-end=\"6404\"\u003etransaminase drift\u003c\/strong\u003e (usually small).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6424\" data-end=\"6566\"\u003e\n\u003cp data-start=\"6426\" data-end=\"6566\"\u003e\u003cstrong data-start=\"6426\" data-end=\"6443\"\u003eCardiac\/bone:\u003c\/strong\u003e Designed to spare \u003cstrong data-start=\"6462\" data-end=\"6469\"\u003eTRα\u003c\/strong\u003e; nonetheless, monitor \u003cstrong data-start=\"6492\" data-end=\"6501\"\u003eHR\/BP\u003c\/strong\u003e and \u003cstrong data-start=\"6506\" data-end=\"6531\"\u003ebone-turnover markers\u003c\/strong\u003e with prolonged use or high dose.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6567\" data-end=\"6643\"\u003e\n\u003cp data-start=\"6569\" data-end=\"6643\"\u003e\u003cstrong data-start=\"6569\" data-end=\"6581\"\u003eHepatic:\u003c\/strong\u003e Periodic \u003cstrong data-start=\"6591\" data-end=\"6602\"\u003eALT\/AST\u003c\/strong\u003e monitoring—particularly in NAFLD\/MASH.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6644\" data-end=\"6754\"\u003e\n\u003cp data-start=\"6646\" data-end=\"6754\"\u003e\u003cstrong data-start=\"6646\" data-end=\"6660\"\u003eEndocrine:\u003c\/strong\u003e Avoid in \u003cstrong data-start=\"6670\" data-end=\"6699\"\u003euntreated hyperthyroidism\u003c\/strong\u003e; use caution with \u003cstrong data-start=\"6718\" data-end=\"6732\"\u003eamiodarone\u003c\/strong\u003e or \u003cstrong data-start=\"6736\" data-end=\"6751\"\u003eiodine load\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6755\" data-end=\"6808\"\u003e\n\u003cp data-start=\"6757\" data-end=\"6808\"\u003e\u003cstrong data-start=\"6757\" data-end=\"6771\"\u003ePregnancy:\u003c\/strong\u003e Avoid (thyroid-axis manipulation).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6809\" data-end=\"6998\"\u003e\n\u003cp data-start=\"6811\" data-end=\"6998\"\u003e\u003cstrong data-start=\"6811\" data-end=\"6833\"\u003eDrug interactions:\u003c\/strong\u003e Potential with \u003cstrong data-start=\"6849\" data-end=\"6874\"\u003ewarfarin (INR shifts)\u003c\/strong\u003e, \u003cstrong data-start=\"6876\" data-end=\"6903\"\u003eCYP inducers\/inhibitors\u003c\/strong\u003e, and agents affecting \u003cstrong data-start=\"6926\" data-end=\"6955\"\u003ethyroid binding\/transport\u003c\/strong\u003e; separate from \u003cstrong data-start=\"6971\" data-end=\"6997\"\u003ebile-acid sequestrants\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"7000\" data-end=\"7045\"\u003e\u003cstrong data-start=\"7000\" data-end=\"7045\"\u003eComparative safety matrix (thyromimetics)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"7047\" data-end=\"7528\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"7047\" data-end=\"7112\"\u003e\n\u003ctr data-start=\"7047\" data-end=\"7112\"\u003e\n\u003cth data-start=\"7047\" data-end=\"7057\" data-col-size=\"sm\"\u003eFeature\u003c\/th\u003e\n\u003cth data-start=\"7057\" data-end=\"7081\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7059\" data-end=\"7080\"\u003eSobetirome (GC-1)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"7081\" data-end=\"7098\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7083\" data-end=\"7097\"\u003eEprotirome\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"7098\" data-end=\"7112\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7100\" data-end=\"7110\"\u003eVK2809\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"7131\" data-end=\"7528\"\u003e\n\u003ctr data-start=\"7131\" data-end=\"7232\"\u003e\n\u003ctd data-start=\"7131\" data-end=\"7154\" data-col-size=\"sm\"\u003eReceptor selectivity\u003c\/td\u003e\n\u003ctd data-start=\"7154\" data-end=\"7174\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7156\" data-end=\"7173\"\u003eTRβ-selective\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7174\" data-end=\"7190\" data-col-size=\"sm\"\u003eTRβ-selective\u003c\/td\u003e\n\u003ctd data-start=\"7190\" data-end=\"7232\" data-col-size=\"sm\"\u003eTRβ-selective (liver-targeted prodrug)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7233\" data-end=\"7289\"\u003e\n\u003ctd data-start=\"7233\" data-end=\"7241\" data-col-size=\"sm\"\u003eRoute\u003c\/td\u003e\n\u003ctd data-start=\"7241\" data-end=\"7252\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7243\" data-end=\"7251\"\u003eOral\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7252\" data-end=\"7259\" data-col-size=\"sm\"\u003eOral\u003c\/td\u003e\n\u003ctd data-start=\"7259\" data-end=\"7289\" data-col-size=\"sm\"\u003eOral (hepatocyte-targeted)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7290\" data-end=\"7407\"\u003e\n\u003ctd data-start=\"7290\" data-end=\"7307\" data-col-size=\"sm\"\u003eLDL\/TG effects\u003c\/td\u003e\n\u003ctd data-start=\"7307\" data-end=\"7337\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7309\" data-end=\"7336\"\u003eRobust (dose-dependent)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7337\" data-end=\"7379\" data-col-size=\"sm\"\u003eRobust (program halted for tox in dogs)\u003c\/td\u003e\n\u003ctd data-start=\"7379\" data-end=\"7407\" data-col-size=\"sm\"\u003eRobust (Phase 2 signals)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7408\" data-end=\"7528\"\u003e\n\u003ctd data-start=\"7408\" data-end=\"7423\" data-col-size=\"sm\"\u003eKey concerns\u003c\/td\u003e\n\u003ctd data-start=\"7423\" data-end=\"7464\" data-col-size=\"sm\"\u003eAxis suppression (manageable), mild HR\u003c\/td\u003e\n\u003ctd data-start=\"7464\" data-end=\"7492\" data-col-size=\"sm\"\u003ePreclinical cartilage tox\u003c\/td\u003e\n\u003ctd data-start=\"7492\" data-end=\"7528\" data-col-size=\"sm\"\u003eAxis suppression, LFTs (monitor)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7530\" data-end=\"7533\"\u003e\n\u003ch2 data-start=\"7535\" data-end=\"7561\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"7563\" data-end=\"7841\"\u003e\n\u003cli data-start=\"7563\" data-end=\"7603\"\u003e\n\u003cp data-start=\"7565\" data-end=\"7603\"\u003e\u003cstrong data-start=\"7565\" data-end=\"7581\"\u003eNot approved\u003c\/strong\u003e for any indication.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7604\" data-end=\"7747\"\u003e\n\u003cp data-start=\"7606\" data-end=\"7747\"\u003eBeing developed for \u003cstrong data-start=\"7626\" data-end=\"7648\"\u003edyslipidemia\/NAFLD\u003c\/strong\u003e (adjunct to standard of care) and \u003cstrong data-start=\"7683\" data-end=\"7702\"\u003erare neurologic\u003c\/strong\u003e indications via \u003cstrong data-start=\"7719\" data-end=\"7744\"\u003eCNS-targeted prodrugs\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7748\" data-end=\"7841\"\u003e\n\u003cp data-start=\"7750\" data-end=\"7841\"\u003eNo sport relevance (not a performance drug), but \u003cstrong data-start=\"7799\" data-end=\"7840\"\u003eoff-label\/compound use is not advised\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7843\" data-end=\"7846\"\u003e\n\u003ch2 data-start=\"7848\" data-end=\"7871\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"7873\" data-end=\"8554\"\u003e\n\u003cli data-start=\"7873\" data-end=\"8021\"\u003e\n\u003cp data-start=\"7875\" data-end=\"8021\"\u003e\u003cstrong data-start=\"7875\" data-end=\"7904\"\u003eCardiometabolic outcomes:\u003c\/strong\u003e ApoB-anchored Phase 3 with \u003cstrong data-start=\"7932\" data-end=\"7940\"\u003eMACE\u003c\/strong\u003e endpoints; combination strategies with \u003cstrong data-start=\"7980\" data-end=\"8018\"\u003estatins, ezetimibe, PCSK9, ANGPTL3\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8022\" data-end=\"8136\"\u003e\n\u003cp data-start=\"8024\" data-end=\"8136\"\u003e\u003cstrong data-start=\"8024\" data-end=\"8043\"\u003eMASH histology:\u003c\/strong\u003e Biopsy-based trials (NASH resolution, fibrosis endpoints) and \u003cstrong data-start=\"8106\" data-end=\"8122\"\u003eMRI-PDFF\/MRE\u003c\/strong\u003e composites.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8137\" data-end=\"8261\"\u003e\n\u003cp data-start=\"8139\" data-end=\"8261\"\u003e\u003cstrong data-start=\"8139\" data-end=\"8164\"\u003eDose-exposure models:\u003c\/strong\u003e Define \u003cstrong data-start=\"8172\" data-end=\"8199\"\u003eTRβ selectivity windows\u003c\/strong\u003e that preserve axis efficacy with minimal \u003cstrong data-start=\"8241\" data-end=\"8248\"\u003eTRα\u003c\/strong\u003e spillover.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8262\" data-end=\"8433\"\u003e\n\u003cp data-start=\"8264\" data-end=\"8433\"\u003e\u003cstrong data-start=\"8264\" data-end=\"8281\"\u003eCNS programs:\u003c\/strong\u003e Optimize \u003cstrong data-start=\"8291\" data-end=\"8302\"\u003eSob-AM2\u003c\/strong\u003e or next-gen brain-penetrant analogs; \u003cstrong data-start=\"8340\" data-end=\"8349\"\u003eVLCFA\u003c\/strong\u003e, \u003cstrong data-start=\"8351\" data-end=\"8375\"\u003emyelin imaging (MTR)\u003c\/strong\u003e, and \u003cstrong data-start=\"8381\" data-end=\"8404\"\u003efunctional outcomes\u003c\/strong\u003e in \u003cstrong data-start=\"8408\" data-end=\"8419\"\u003eALD\/AMN\u003c\/strong\u003e and \u003cstrong data-start=\"8424\" data-end=\"8430\"\u003eMS\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8434\" data-end=\"8554\"\u003e\n\u003cp data-start=\"8436\" data-end=\"8554\"\u003e\u003cstrong data-start=\"8436\" data-end=\"8458\"\u003eSafety registries:\u003c\/strong\u003e Long-term \u003cstrong data-start=\"8469\" data-end=\"8485\"\u003ethyroid axis\u003c\/strong\u003e, \u003cstrong data-start=\"8487\" data-end=\"8505\"\u003ecardiac rhythm\u003c\/strong\u003e, \u003cstrong data-start=\"8507\" data-end=\"8523\"\u003ebone density\u003c\/strong\u003e, and \u003cstrong data-start=\"8529\" data-end=\"8540\"\u003ehepatic\u003c\/strong\u003e surveillance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"8556\" data-end=\"8559\"\u003e\n\u003ch3 data-start=\"8561\" data-end=\"8584\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"8586\" data-end=\"9480\"\u003e\n\u003cli data-start=\"8586\" data-end=\"8741\"\u003e\n\u003cp data-start=\"8588\" data-end=\"8741\"\u003e\u003cstrong data-start=\"8588\" data-end=\"8647\"\u003eCirculation; Atherosclerosis; Journal of Lipid Research\u003c\/strong\u003e — TRβ agonism, LDLR up-regulation, and lipoprotein remodeling with sobetirome-class agents.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8742\" data-end=\"8843\"\u003e\n\u003cp data-start=\"8744\" data-end=\"8843\"\u003e\u003cstrong data-start=\"8744\" data-end=\"8779\"\u003eHepatology; Liver International\u003c\/strong\u003e — TRβ-driven steatosis reduction and NAFLD biomarker changes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8844\" data-end=\"8953\"\u003e\n\u003cp data-start=\"8846\" data-end=\"8953\"\u003e\u003cstrong data-start=\"8846\" data-end=\"8896\"\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism\u003c\/strong\u003e — Early human lipid\/thyroid-axis data with sobetirome.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8954\" data-end=\"9104\"\u003e\n\u003cp data-start=\"8956\" data-end=\"9104\"\u003e\u003cstrong data-start=\"8956\" data-end=\"9035\"\u003eArteriosclerosis, Thrombosis, and Vascular Biology; Cardiovascular Research\u003c\/strong\u003e — Atheroprotection mechanisms (macrophage efflux, plaque biology).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9105\" data-end=\"9204\"\u003e\n\u003cp data-start=\"9107\" data-end=\"9204\"\u003e\u003cstrong data-start=\"9107\" data-end=\"9137\"\u003eBrain; Annals of Neurology\u003c\/strong\u003e — TRβ in oligodendrocyte maturation and remyelination paradigms.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9205\" data-end=\"9354\"\u003e\n\u003cp data-start=\"9207\" data-end=\"9354\"\u003e\u003cstrong data-start=\"9207\" data-end=\"9252\"\u003eScience Translational Medicine; Neurology\u003c\/strong\u003e — Sobetirome\/Sob-AM2 lowering VLCFAs in \u003cstrong data-start=\"9293\" data-end=\"9302\"\u003eABCD1\u003c\/strong\u003e models and translational steps for \u003cstrong data-start=\"9338\" data-end=\"9351\"\u003eX-ALD\/AMN\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9355\" data-end=\"9480\"\u003e\n\u003cp data-start=\"9357\" data-end=\"9480\"\u003e\u003cstrong data-start=\"9357\" data-end=\"9388\"\u003eCell Metabolism; Metabolism\u003c\/strong\u003e — Energy-expenditure and hepatic transcriptional programs under thyroid hormone mimetics.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"6654\" data-start=\"6575\"\u003e \u003c\/p\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684858720594,"sku":null,"price":120.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/sobetirome_10000mcg.png?v=1770834892","url":"https:\/\/sciencepeptideslab.com\/products\/sobetiromegc-1","provider":"Science Peptides Lab","version":"1.0","type":"link"}